Animal Gastroesophageal Reflux Disease Market Report 2026

The animal gastroesophageal reflux disease market size has grown strongly in recent years. It will grow from $1.98 billion in 2025 to $2.16 billion in 2026 at a compound annual growth rate (CAGR) of 8.8%. The growth in the historic period can be attributed to limited awareness of animal gerd among veterinarians, high prevalence of gerd in companion animals, lack of advanced diagnostics in veterinary hospitals, reliance on generic medications, growth of veterinary clinics and hospitals.

The animal gastroesophageal reflux disease market size is expected to see strong growth in the next few years. It will grow to $2.99 billion in 2030 at a compound annual growth rate (CAGR) of 8.5%. The growth in the forecast period can be attributed to development of advanced diagnostic techniques such as endoscopy and manometry, increasing focus on nutritional and dietary interventions, rising adoption of otc and prescription drugs, expansion of veterinary e-commerce channels, integration of ai and digital platforms for personalized treatment. Major trends in the forecast period include rising adoption of endoscopy and ph monitoring for gerd diagnosis, increasing use of nutritional supplements and dietary modifications in management, growth in prescription and otc medication availability for companion animals, expansion of minimally invasive surgical interventions for gerd treatment, customized treatment protocols for livestock and companion animals.

The increasing humanization of pets is expected to drive the growth of the animal gastroesophageal reflux disease market. Humanization of pets refers to the rising trend of pet owners treating their animals more like human family members, attributing human-like emotions, needs, and behaviors to them. This trend is fueled by the strengthening emotional bonds between owners and their pets, which boosts demand for specialized healthcare, premium diets, and wellness products that align with human standards. Humanization also raises awareness of health issues such as gastroesophageal reflux disease (GERD), prompting attentive owners to seek veterinary care and increasing demand for diagnostics, treatments, and preventive options. For example, in April 2024, according to the American Pet Products Association, a US-based not-for-profit industry association, 86.9 million US households had a pet in 2023-2024, representing 66% of households, up from 62% in 2022. Thus, the growing humanization of pets is propelling the animal gastroesophageal reflux disease market.

The rising expenditure on animal healthcare is expected to drive the growth of the animal gastroesophageal reflux disease market going forward. Animal healthcare encompasses the care and treatment provided to animals to prevent diseases, diagnose health problems, deliver medical treatment, and maintain overall health and well-being throughout their lives. Spending on animal healthcare is increasing as pet owners prioritize preventive and advanced medical care to enhance the quality and longevity of their animals’ lives, leading to greater utilization of veterinary services, diagnostics, and treatments. Management of animal gastroesophageal reflux disease contributes to higher healthcare spending due to repeated veterinary consultations, diagnostic tests, long-term medication, and dietary management required to control symptoms and prevent complications. For instance, in March 2025, according to the American Pet Products Association, a US-based non-profit organization, total spending in 2024 on Veterinary Care & Product Sales amounted to $39.8 billion. Therefore, rising expenditure on animal healthcare is driving the growth of the animal gastroesophageal reflux disease market.

Leading players in the animal gastroesophageal reflux disease market are developing specialized diets that support gastrointestinal health to improve digestion and manage symptoms of gastroesophageal reflux disease in pets. Gastrointestinal support diets are specially formulated pet foods designed to alleviate and manage gastrointestinal disorders. These diets typically contain easily digestible ingredients, balanced nutrients, and added fibers or probiotics to promote digestive health and overall well-being. For example, in April 2024, Royal Canin, a USA-based subsidiary of Mars Incorporated and manufacturer of cat and dog food, expanded its veterinary gastrointestinal (GI) portfolio by introducing five new diets aimed at improving gastrointestinal health in pets. Developed in collaboration with researchers, veterinarians, and specialists, these diets target GI issues in both dogs and cats, including food-responsive sensitivities and fat-restricted diets. New options include gastrointestinal low-fat, hydrolyzed protein canine, and gastrointestinal hydrolyzed protein feline diets, all formulated with highly digestible ingredients to support long-term gastrointestinal health.

Major companies operating in the animal gastroesophageal reflux disease market are Zoetis Inc., VCA Animal Hospitals, Petco Health and Wellness Company Inc., Merck Animal Health, Boehringer Ingelheim Animal Health, Elanco Animal Health Incorporated, Hill's Pet Nutrition Inc., IDEXX Laboratories Inc., Ceva Santé Animale, Virbac S.A., Phibro Animal Health Corporation, Dechra Pharmaceuticals PLC, Blue Buffalo Company Ltd., Vetoquinol S.A., Antech Diagnostics, Heska Corporation, WellPet LLC, McNeil Consumer Pharmaceuticals Co., Wag Labs Inc., VetPartners Limited, BioZyme Inc., Zomedica Corp., NexGen Pharmaceuticals LLC.

North America was the largest region in the animal gastroesophageal reflux disease market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the animal gastroesophageal reflux disease market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the animal gastroesophageal reflux disease market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the animal gastroesophageal reflux disease market by increasing the cost of imported diagnostic devices, medications, and surgical instruments, impacting veterinary hospitals, clinics, and e-commerce channels, particularly in North America and Europe. Prescription medications and advanced diagnostic tools like endoscopy and pH monitoring are most affected. On the positive side, tariffs are encouraging local manufacturing and regional production of GERD-related products, potentially enhancing supply stability and reducing import dependency.

The animal gastroesophageal reflux disease market research report is one of a series of new reports that provides animal gastroesophageal reflux disease market statistics, including animal gastroesophageal reflux disease industry global market size, regional shares, competitors with a animal gastroesophageal reflux disease market share, detailed animal gastroesophageal reflux disease market segments, market trends and opportunities, and any further data you may need to thrive in the animal gastroesophageal reflux disease industry. This animal gastroesophageal reflux disease market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Animal gastroesophageal reflux disease (GERD) occurs when stomach acid or bile flows back into the esophagus, leading to irritation and inflammation. This condition can cause symptoms such as vomiting, regurgitation, weight loss, and discomfort during eating. Diagnosing and treating GERD in animals aims to relieve discomfort, enhance quality of life, and prevent complications such as esophagitis, ulcers, or strictures.

The main product types for managing animal GERD include treatment and diagnostic options. Treatment involves products designed to manage and alleviate GERD symptoms in animals, such as antacids, proton pump inhibitors, and other medications that reduce stomach acid and support digestive health. These treatments are available in over-the-counter (OTC) and prescription forms, with administration routes including oral and injectable. GERD treatments are used for both companion animals and livestock. Distribution channels for these products include veterinary hospitals and clinics, retail pharmacies, and e-commerce platforms.

The animal gastroesophageal reflux disease market consists of revenues earned by entities by providing services such as specialized veterinary care, prescription medications, diagnostic testing and nutritional counseling. The market value includes the value of related goods sold by the service provider or included within the service offering. The animal gastroesophageal reflux disease market also includes sales of gastrointestinal support diets, medications and hydrolyzed protein diets. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.